Using AI to predict treatment outcomes in lung cancer patients with brain metastases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to utilize deep learning to analyze imaging features of brain and lung lesions in patients with advanced non-small cell lung cancer (NSCLC) who have brain metastases. By collecting regular contrast-enhanced chest CT and brain MRI scans from participants receiving third-generation EGFR-TKI treatment, the study seeks to construct a multimodal model that predicts treatment efficacy and survival. The model will also help identify high-risk patients who may benefit from upfront cranial radiotherapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Pathologically confirmed non-small cell lung cancer;
* clinical stage IV (AJCC, 8th edition, 2017);
* EGFR sensitive mutations: EGFR L858R, EGFR exon 19 deletion;
* age≥18 years old;
* KPS score≥70;
* brain metastases at diagnosis;
* complete systemic imaging (including brain MRI) before third-generation EGFR-TKI treatment;
* received standard third-generation EGFR-TKI therapy (monotherapy or combined with brain radiotherapy);
* willing to cooperate with the follow-up after third-generation EGFR-TKI treatment;
* informed consent of the patient.

Exclusion Criteria:

* Multiple primary or metastatic tumors (except early skin cancer, cervical carcinoma in situ that has been treated radically, with no recurrence or progression for more than 5 years);
* Pregnant or lactating women who, as judged by the investigator, were not candidates for brain MRI;
* EGFR sensitive mutations were negative or EGFR mutation status was not detected.
* Uncontrolled epilepsy, central nervous system disease, or history of mental disorders, judged by the researcher to potentially interfere with the signing of the informed consent form or affect patient compliance.

Where it's running

• Shanghai Cancer center
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: zhengfei Zhu
• Email: fuscczzf@163.com
• Phone: +86-18017312901

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• SRS Before Surgery for Brain Metastases to Try Better Surgical Outcomes

  This study tests whether giving stereotactic radiosurgery to a single brain metastasis before its surgical removal can reduce cancer spread during surgery and improve recovery.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07802353

• AMT-116 vs doctor’s choice in advanced non-squamous NSCLC that is EGFR-wild and progressed after platinum and PD-1/PD-L1 therapy

  This study tests AMT-116 in adults with advanced non-squamous NSCLC that is EGFR-wild, comparing different doses to doctor’s choice after prior platinum and immunotherapy.

  Recruiting Phase 2/3 Multitude Therapeutics Inc. · Port Saint Lucie, Florida and 6 other locations · NCT07718737

• Connectome-guided network planning for brain tumor surgery in eloquent areas

  This study tests whether using patient-specific brain network maps from diffusion MRI can help surgeons plan and guide brain tumor removal in eloquent areas.

  Recruiting ARNAS Civico Di Cristina Benfratelli Hospital · Palermo, PA · NCT07717827

• SHY-ONC6: a new anti-cancer drug tested in adults with advanced solid tumors

  This early-phase study tests SHY-ONC6 to see if it is safe and can help people with advanced solid tumors after standard therapies have failed.

  Recruiting at 3 sites Phase 1 SHY Therapeutics · Scottsdale, Arizona and 2 other locations · NCT07705334

• Radiotherapy with chemotherapy plus adebrelimab and bevacizumab for TNBC with brain metastases

  This phase II study tests a combination of radiotherapy, cisplatin or carboplatin, adebrelimab, and bevacizumab in adults with triple-negative breast cancer that has spread to the brain.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07638852

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.